证券代码：603387 证券简称：基蛋生物 公告编号：2023-022 基蛋生物科技股份有限公司 关于 2023 年半年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股分配比例：向全体股东每10股派发人民币1元（含税）。 本次利润分配以实施权益分派股权登记日总股本数为基数，具体日期将 在权益分派实施公告中明确,在实施权益分派的股权登记日前公司总股本发生变 动的，拟维持分配总额不变，相应调整每股分配比例，并将另行公告具体调整情 况。 一、利润分配方案内容 基蛋生物科技股份有限公司（合并报表） 2023年1-6月实现净利润 171,580,000.10元，其中归属上市公司股东的净利润168,720,454.45元。2023年 半年度公司（合并报表）可供分配利润1,471,522,388.59元，母公司可供分配利 润1,249,703,008.38元（数据未经审计）。 基于对公司未来发展的良好预期，综合考虑公司经营现状、资产规模及盈余 情况，在保证公司正常经营和长远发展的前提下，为回报全 ...

Financial Performance - In 2022, the company achieved a net profit of RMB 503,944,698.54, with a net profit attributable to shareholders of RMB 498,909,980.40[6]. - The company proposed a cash dividend of RMB 3 per 10 shares, amounting to a total cash dividend of RMB 152,146,055.10, which represents 30.50% of the net profit attributable to shareholders[7]. - The total distributable profit for 2022 was RMB 1,454,947,989.25, after accounting for the profit distribution and retained earnings[6]. - The parent company reported a net profit of RMB 433,531,627.04 for 2022, with a total distributable profit of RMB 1,228,815,194.65[6]. - The company's operating revenue for 2022 reached ¥1,821,860,703.15, representing a year-on-year increase of 29.97%[25]. - The net profit attributable to shareholders for 2022 was ¥498,909,980.40, up 25.04% compared to the previous year[25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 25.59% to ¥461,538,014.58[25]. - Basic earnings per share for 2022 were ¥0.98, an increase of 24.05% from ¥0.79 in 2021[26]. - The weighted average return on equity for 2022 was 21.76%, up from 20.43% in 2021[26]. - Total assets at the end of 2022 amounted to ¥3,677,437,948.24, reflecting a year-on-year growth of 17.19%[25]. Risk Management and Compliance - The company has outlined various risk factors that may affect its future development strategies and operational goals[10]. - The company has no non-operating fund occupation by controlling shareholders or related parties[9]. - The company has not violated decision-making procedures for external guarantees[10]. - The board of directors has ensured the authenticity, accuracy, and completeness of the annual report[4]. - The company received a standard unqualified audit report from Zhongtian Yun Accounting Firm[5]. Research and Development - The company achieved a research and development investment of 26,205.90 million yuan, a year-on-year increase of 40.19%, accounting for 14.38% of operating revenue[49]. - The number of R&D personnel increased to 632, up by 184 from the beginning of 2022[49]. - The company has 500 valid patents as of December 31, 2022, with 310 authorized patents, including 30 invention patents[49]. - The company has developed eight major technology platforms, including POCT, chemiluminescence, biochemical testing, and molecular diagnostics, enhancing its product system from single POCT products to a diverse range[70]. - The company is committed to continuous innovation in product development, focusing on unmet clinical needs[50]. Product Development and Market Expansion - The company launched several new products, including the MAGICL6200 fully automated chemiluminescence analyzer (400T/H) and the CM1000 fully automated biochemical analyzer (1000T/H)[50]. - The company launched the Metis600 emergency blood cell line, which integrates multiple testing capabilities for clinical needs, including blood routine, inflammation, cardiovascular, and glycation tests[40]. - The company is focusing on expanding its market share in grade hospitals by increasing penetration in previously untapped departments[38]. - The company has expanded its chemiluminescence product line to 78 items, including 11 cardiovascular projects, maintaining a leading position in the market[44]. - The company aims to further develop its product offerings in areas such as coagulation series and liver cancer screening, enhancing its competitive edge in the chemiluminescence market[46]. Marketing and Sales Strategy - The company implemented a dual-driven marketing reform strategy focusing on "core" and "collaboration" to enhance growth[52]. - The company has established a comprehensive after-sales service system with over 200 frontline engineers and 30 technical engineers nationwide[59]. - The company is focusing on proactive maintenance and upgrades for large instruments to improve customer satisfaction[59]. - The company aims to leverage new policies to enhance the construction of county-level medical institutions, benefiting the IVD sector[66]. - The company is focusing on expanding its direct sales team to enhance customer loyalty and market barriers[81]. Corporate Governance - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with relevant laws and regulations[153]. - The supervisory board has 3 members, including 1 employee representative, fulfilling its duties to oversee financial conditions and major matters[154]. - The company has established a robust information disclosure system, ensuring timely and accurate communication of significant information to shareholders[155]. - The company maintains independent operations with complete assets, personnel, and financial systems, ensuring no conflicts of interest with controlling shareholders[156]. - The company has conducted 3 shareholder meetings during the reporting period, ensuring equal rights for all shareholders and no rejected resolutions[159]. Employee and Management Practices - The company has established a comprehensive welfare system for employees, including various benefits to enhance employee satisfaction and belonging[184]. - The company conducted training programs focusing on R&D processes, safety production, and management talent development during the reporting period[185]. - The company’s remuneration policy aims to align employee development with corporate interests, ensuring fair and competitive compensation[184]. - The total remuneration for all directors, supervisors, and senior management during the reporting period amounted to 7.0898 million yuan[170]. Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25% and aiming to reach 1.875 billion RMB[167]. - The company plans to invest 200 million RMB in marketing to support the launch of new products and enhance brand visibility[167]. - The company aims to establish wholly-owned subsidiaries in Hong Kong, Singapore, and Germany, with plans to set up offices in Southeast Asia, South Asia, and Africa to deepen local market penetration[143]. - The company plans to increase R&D investment and strengthen technological innovation to enhance core competitiveness and improve operational performance[151].

Financial Performance - The company's operating revenue for Q1 2023 was ¥384,316,306.14, a decrease of 32.66% compared to the same period last year[2] - Net profit attributable to shareholders was ¥121,526,036.35, down 44.44% year-on-year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥100,536,845.57, a decline of 54.32%[2] - Basic and diluted earnings per share were both ¥0.24, down 44.19% from the previous year[2] - Total operating revenue for Q1 2023 was ¥384,316,306.14, a decrease of 32.7% compared to ¥570,715,217.73 in Q1 2022[18] - Net profit for Q1 2023 was ¥124,371,119.11, a decline of 43.7% from ¥220,693,233.53 in Q1 2022[19] - The total comprehensive income for Q1 2023 was ¥124,267,374.11, down from ¥220,693,233.53 in Q1 2022[20] Cash Flow - The net cash flow from operating activities was ¥13,484,563.45, representing a significant drop of 79.84%[2] - In Q1 2023, the cash inflow from operating activities was CNY 528,041,082.97, a decrease of 21.1% compared to CNY 669,337,060.24 in Q1 2022[22] - The net cash flow from operating activities was CNY 13,484,563.45, down 79.9% from CNY 66,898,060.91 in the same period last year[22] - Cash inflow from investment activities totaled CNY 186,730,257.77, significantly up from CNY 42,531,695.56 in Q1 2022[22] - The net cash flow from investment activities was CNY 103,596,691.92, compared to a negative CNY 15,619,831.84 in Q1 2022[22] - Cash inflow from financing activities was CNY 297,813,000.00, down from CNY 376,609,940.27 in the previous year[23] - The net cash flow from financing activities was negative CNY 26,790,759.52, a decline from positive CNY 51,380,646.72 in Q1 2022[23] - The ending balance of cash and cash equivalents was CNY 732,976,882.93, down from CNY 1,045,222,484.13 at the end of Q1 2022[23] - The company reported a cash increase of CNY 88,332,104.53 in Q1 2023, compared to CNY 100,071,255.50 in Q1 2022[23] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥3,671,973,340.42, a slight decrease of 0.15% from the end of the previous year[3] - The company's total liabilities as of Q1 2023 amounted to ¥892,257,607.28, a decrease from ¥1,012,840,595.85 in the previous period[17] - The total equity attributable to shareholders was ¥2,603,189,418.94, an increase from ¥2,482,468,375.18 year-over-year[17] - Shareholders' equity attributable to the parent company increased by 4.86% to ¥2,603,189,418.94 compared to the end of the previous year[3] Revenue Breakdown - The decline in revenue was primarily attributed to a decrease in COVID-related business compared to the previous year[6] - In Q1 2023, the company achieved a revenue of 23.52 million RMB from COVID-related business, a significant decline of 93.11% year-on-year[10] - Excluding COVID revenue, the company's self-produced products generated a total revenue of 286.28 million RMB, marking a year-on-year increase of 71.69%[10] - The POCT product line reported a revenue of 213.16 million RMB, reflecting a year-on-year growth of 56.21%[11] - The sales revenue from the chemical luminescence product line reached 43.18 million RMB, showing a substantial increase of 277.64% year-on-year[11] Research and Development - The company continues to focus on R&D, aiming to enhance competitiveness across its IVD product lines[12] - Research and development expenses for Q1 2023 were ¥55,164,547.70, up from ¥50,924,275.03 in Q1 2022, indicating a focus on innovation[18] - The company plans to accelerate the market validation and coverage of the newly launched Metis6000 fully automated immunoassay line[11] Shareholder Information - The company had a total of 38,070 common shareholders at the end of the reporting period[8]

证券代码：603387 证券简称：基蛋生物 公告编号：2023-012 基蛋生物科技股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度的经营成果 及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内 就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2023 年 05 月 18 日上午 09:00-10:00 会议召开时间：2023年05月18日(星期四)上午09:00-10:00 会议召开地点：上海证券交易所上证路演中心 （网址：http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 （二）会议召开地点：上证路演中心 （三）会议召开方式：上证路演中心网络互动 三、参加人员 投资者可于2023年05月11日(星期四)至05月17日(星期三)16:00前登录 上证路演中心网站首页点击"提问预 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥403,956,352.10, representing a year-on-year increase of 25.50%[3] - The net profit attributable to shareholders for Q3 2022 was ¥145,399,343.30, reflecting a significant increase of 76.76% compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2022 was ¥135,619,425.05, up by 83.96% year-on-year[3] - For the first three quarters of 2022, the company achieved a total revenue of 1.377 billion RMB, representing a year-over-year growth of 49.34%[11] - The net profit attributable to shareholders for the same period was 475 million RMB, an increase of 87.74% compared to the previous year[11] - Net profit for the first three quarters of 2022 was ¥481,071,216.93, representing a 83.5% increase from ¥262,123,493.95 in the same period of 2021[20] - The company reported a total comprehensive income of ¥481,643,628.87 for the third quarter of 2022, compared to ¥262,121,862.08 in the same quarter of 2021[21] Cash Flow and Liquidity - The cash flow from operating activities for the year-to-date period increased by 113.33% to ¥207,880,331.23[3] - The net cash flow from operating activities for Q3 2022 was ¥207,880,331.23, an increase from ¥97,446,913.82 in Q3 2021, representing a growth of approximately 113%[24] - Total cash inflow from operating activities amounted to ¥1,456,238,026.02, compared to ¥1,106,288,768.88 in the previous year, indicating a year-over-year increase of about 32%[24] - Cash outflow from operating activities was ¥1,248,357,694.79, up from ¥1,008,841,855.06, reflecting a rise of approximately 24%[24] - The company’s cash and cash equivalents as of September 30, 2022, amounted to approximately 1.135 billion RMB, up from 968.9 million RMB at the end of 2021[15] - The cash and cash equivalents at the end of the period reached ¥1,133,577,261.76, up from ¥939,447,825.95 at the end of Q3 2021, representing an increase of approximately 21%[25] Assets and Equity - The total assets at the end of the reporting period were ¥3,654,181,309.98, a growth of 16.45% from the end of the previous year[4] - The equity attributable to shareholders at the end of the reporting period was ¥2,458,822,357.52, marking a 16.73% increase year-on-year[4] - Total assets as of September 30, 2022, were approximately 3.654 billion RMB, compared to 3.138 billion RMB at the end of 2021[16] - Total equity reached ¥2,641,369,078.62, up from ¥2,274,029,770.25 in the same period of 2021[18] Research and Development - Research and development investment for the first three quarters reached 170 million RMB, a year-over-year increase of 30.17%[13] - Research and development expenses for the first three quarters of 2022 were ¥151,894,491.01, an increase from ¥119,364,029.14 in the same period of 2021[19] Product Development and Market Strategy - The company attributed the revenue growth to the expansion of its product line and effective control of domestic COVID-19, leading to a significant increase in sales[6] - The company reported a year-to-date net profit growth driven by increased sales of self-produced products and improved cost control[6] - The company plans to launch several new products in Q4 2022, including the fully automated coagulation analyzer CA5200 and the high-speed fully automated chemiluminescence analyzer MAGICL6200[13] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[19] Inventory and Operating Costs - The company’s inventory increased to approximately 376 million RMB, up from 252 million RMB in the previous year[16] - Total operating costs for the first three quarters of 2022 were ¥847,993,776.91, up 30.6% from ¥649,303,464.59 in the previous year[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 37,376[8] - Basic and diluted earnings per share for the third quarter of 2022 were both ¥0.93, compared to ¥0.50 in the same quarter of 2021[21]

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2022, representing a year-on-year increase of 15%[12]. - The company's operating revenue for the first half of the year reached ¥973,211,496.78, representing a 62.12% increase compared to ¥600,288,159.94 in the same period last year[20]. - Net profit attributable to shareholders increased by 93.03% to ¥329,801,726.74 from ¥170,856,236.75 year-on-year[22]. - The net profit after deducting non-recurring gains and losses rose by 107.68% to ¥324,746,556.32 compared to ¥156,371,441.63 in the previous year[22]. - The company's cash flow from operating activities increased by 13.80% to ¥139,398,475.54, up from ¥122,489,994.89 in the same period last year[22]. - Basic earnings per share rose by 91.17% to ¥0.65 from ¥0.34 year-on-year[21]. - The company's total assets grew by 10.35% to ¥3,462,750,351.49 from ¥3,137,931,357.50 at the end of the previous year[20]. - The net assets attributable to shareholders increased by 9.76% to ¥2,311,900,340.42 from ¥2,106,400,196.02 at the end of the previous year[20]. - The company achieved operating revenue of 973.21 million yuan, a year-on-year increase of 62.12%[51]. - The revenue from in vitro diagnostic business was 831 million yuan, reflecting a significant growth of 90.04%[51]. - The company reported a total operating profit of ¥341,905,801.15 for the first half of 2022, up from ¥150,030,047.62 in the same period of 2021, representing a growth of about 128.5%[140]. Market Expansion and Product Development - User data indicated an increase in active users by 25%, reaching a total of 5 million users by June 30, 2022[12]. - The company plans to launch three new products in the next quarter, focusing on point-of-care testing (POCT) technology[12]. - Market expansion efforts include entering two new international markets, aiming for a 10% increase in overseas sales by the end of 2022[12]. - The company is actively expanding its product lines and pursuing overseas strategies, contributing to revenue growth[22]. - The company is actively promoting new projects in various diagnostic areas, including myocardial markers, inflammation, and tumor markers[36]. - The company is focusing on market expansion, targeting a 30% increase in market share in key regions over the next two years[176]. - A strategic acquisition was announced, which is expected to contribute an additional 500 million in revenue annually starting next fiscal year[178]. - The company is exploring potential mergers and acquisitions to enhance its market share and operational capabilities[168]. Research and Development - The company is investing RMB 100 million in R&D for new diagnostic technologies, with a focus on enhancing product accuracy and speed[12]. - R&D investment for the first half of 2022 was 116.16 million yuan, representing a year-on-year increase of 45.73% and accounting for 11.93% of operating revenue[47]. - The company has established seven major technology platforms, enhancing its core competitiveness in the in vitro diagnostic industry[46]. - The company is committed to enhancing its R&D capabilities, focusing on small and high-speed chemiluminescence instruments and comprehensive reagent support[44]. - The company is actively researching and developing products for emerging health threats, such as monkeypox, and has completed EU registration for these products[37]. - The company has obtained 53 new product registration certificates in the first half of 2022, bringing the total to 1,209, including 359 domestic and 850 foreign certificates[56]. Operational Efficiency - The company has established a dynamic capacity adjustment mechanism to respond quickly to market demand, ensuring timely order fulfillment and maintaining reasonable inventory levels[38]. - The company emphasizes cost control through optimized supply chain management and has achieved favorable procurement costs, enhancing overall product competitiveness[37]. - The company has a robust production model that combines sales forecasting with a make-to-order approach, ensuring efficient production and inventory management[38]. - The company has implemented a flexible sales model that combines distribution and direct sales, enhancing its ability to innovate and respond to clinical demands[40]. Financial Management and Shareholder Commitments - The company reported a net cash outflow from investing activities of ¥45,355,737.88, a significant decrease of 141.61% from a net inflow of ¥109,010,969.85 in the previous period[60]. - The company has established commitments to avoid any potential competition from its actual controller and related parties[103]. - The controlling shareholder has pledged not to transfer shares for 36 months post-IPO, with specific conditions for any future share reductions[96]. - The company will notify the public three trading days in advance of any share reduction plans, including quantity and price range[100]. - The commitments made by shareholders and senior management are subject to public supervision and regulatory oversight[102]. Environmental and Social Responsibility - The company reported that it does not belong to the key pollutant discharge units and has implemented appropriate measures for environmental protection[82]. - The wastewater generated by the company meets the Class 3 standard of the Comprehensive Wastewater Discharge Standard (GB8979-1996) after pretreatment[83]. - The company has installed an online monitoring system for wastewater discharge, ensuring compliance with environmental standards[83]. - The company donated 644,000 RMB to the University of Science and Technology of China for COVID-19 crisis management training for medical personnel and related patients[89].

Financial Performance - In 2021, the company's POCT segment achieved revenue of 0.923 billion CNY, a 62% increase year-on-year [2] - The overall revenue growth reached 76%, with the immunology segment generating sales of 95.86 million CNY [2] - The hemostasis segment reported revenue of 40.24 million CNY, reflecting a 107% year-on-year growth [2] Market Strategy and Challenges - The company views centralized procurement as both a challenge and an opportunity, aiming to enhance market share and drive growth [3] - The company plans to leverage experiences from Anhui's centralized procurement to adapt to various forms of procurement reforms nationwide [3] Product Development and Feedback - The small luminescence product, Magicl6000, has received positive market feedback due to its compact size and high automation [3] - The company plans to launch a small automated production line by Q4 2022, integrating multiple instruments for combined testing [3][4] Future Plans and Innovations - The Getein1600 has been installed in over 6,000 units, with annual installations exceeding 1,000 [3] - The company is set to introduce the BHA-5100 fully automated blood cell analyzer and a new small production line in the second half of 2022 [4] - The development of the Getein3200 biochemical immunoassay analyzer aims to provide rapid results, with a target of 3 minutes for dry biochemical projects [4] Strategic Focus - The company emphasizes the importance of conventional product development for sustained performance growth, expanding into IVD across various fields [4] - There is a strategic shift towards high-end hospitals, with a focus on automation and quality control improvements [4]

2021 年年度报告 公司代码：603387 公司简称：基蛋生物 基蛋生物科技股份有限公司 2021 年年度报告 二零二二年四月 中国 南京 1 / 251 2021 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 中天运会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人苏恩本、主管会计工作负责人倪文及会计机构负责人（会计主管人员）倪文声明： 保证年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 经中天运会计师事务所（特殊普通合伙）审计，基蛋生物科技股份有限公司（合并报表）2021 年度实现净利润41,201.13万元，其中归属上市公司股东的净利润39,899.00万元，提取盈余公积 金3,144.11万元，加年初未分配利润84,816.89万元，减2020年已对股东分配的现金股利9,316.08 万元，2021年度公司累计可供分配利润112, ...

[Major Financial Data](index=1&type=section&id=%E4%B8%80%E3%80%81%20%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%95%B0%E6%8D%AE) This section provides an overview of the company's key financial performance and position [Key Accounting Data and Financial Indicators](index=1&type=section&id=(%E4%B8%80)%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) In Q1 2022, the company achieved strong performance growth, with operating revenue increasing by 106.80% year-over-year and net profit attributable to shareholders surging by 249.06%, demonstrating excellent profitability and operational efficiency Key Financial Indicators for Q1 2022 | Indicator | Current Period | YoY Change (%) | | :--- | :--- | :--- | | Operating Revenue (CNY) | 570,715,217.73 | 106.80% | | Net Profit Attributable to Shareholders (CNY) | 218,721,114.67 | 249.06% | | Net Profit Attributable to Shareholders (Excluding Non-recurring Items) (CNY) | 220,098,447.71 | 245.95% | | Net Cash Flow from Operating Activities (CNY) | 66,898,060.91 | 465.85% | | Basic Earnings Per Share (CNY/share) | 0.61 | 252.84% | | Weighted Average Return on Net Assets (%) | 10.18% | Increased 6.83 percentage points | | **Indicator** | **End of Current Period** | **Change from End of Previous Year (%)** | | Total Assets (CNY) | 3,561,523,415.57 | 13.50% | | Total Equity Attributable to Shareholders (CNY) | 2,325,734,004.11 | 10.41% | [Non-recurring Gains and Losses Items and Amounts](index=2&type=section&id=(%E4%BA%8C)%E9%9D%9E%E7%BB%8F%E5%B8%B8%E6%80%A7%E6%8D%9F%E7%9B%8A%E9%A1%B9%E7%9B%AE%E5%92%8C%E9%87%91%E9%A2%9D) During the reporting period, the company's total non-recurring gains and losses amounted to **-1.38 million CNY**, primarily due to a **-8.31 million CNY** loss from changes in fair value of financial assets, offset by **4.38 million CNY** in government grants and **2.74 million CNY** in entrusted investment income Details of Non-recurring Gains and Losses | Item | Amount (CNY) | | :--- | :--- | | Government Grants | 4,382,496.77 | | Gains/Losses from Entrusted Investments or Asset Management | 2,735,476.61 | | Gains/Losses from Changes in Fair Value of Financial Assets/Liabilities | -8,305,566.58 | | Other Non-operating Income and Expenses | -372,744.44 | | Gains/Losses from Disposal of Non-current Assets | 221,515.20 | | **Total** | **-1,377,333.04** | [Analysis of Key Financial Indicator Changes](index=3&type=section&id=(%E4%B8%89)%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E3%80%81%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87%E5%8F%91%E7%94%9F%E5%8F%98%E5%8A%A8%E7%9A%84%E6%83%85%E5%86%B5%E3%80%81%E5%8E%9F%E5%9B%A0) The significant growth in the company's key financial indicators is primarily attributed to increased sales from overseas business expansion, enhanced profitability due to a higher proportion of self-produced product sales and strengthened cost control, and improved operating cash flow from increased sales collections - Operating revenue increased by **106.80%** year-over-year, primarily due to increased overseas business and significant sales scale growth in Q1 2022[7](index=7&type=chunk) - Net profit attributable to the parent company increased by **249.06%** year-over-year, mainly due to increased profit from a higher proportion of self-produced product sales, coupled with strengthened operational management and cost control, enhancing core business profitability[7](index=7&type=chunk) - Net cash flow from operating activities increased by **465.85%** year-over-year, primarily due to domestic and international business growth, expanded revenue scale, and increased sales collections[7](index=7&type=chunk)[8](index=8&type=chunk) [Shareholder Information](index=5&type=section&id=%E4%BA%8C%E3%80%81%20%E8%82%A1%E4%B8%9C%E4%BF%A1%E6%81%AF) This section details the company's shareholder structure and key shareholding positions [Shareholding Status of Shareholders](index=5&type=section&id=(%E4%B8%80)%E6%99%AE%E9%80%9A%E8%82%A1%E8%82%A1%E4%B8%9C%E6%80%BB%E6%95%B0%E5%92%8C%E8%A1%A8%E5%86%B3%E6%9D%83%E6%81%A2%E5%A4%8D%E7%9A%84%E4%BC%98%E5%85%88%E8%82%A1%E8%82%A1%E4%B8%9C%E6%95%B0%E9%87%8F%E5%8F%8A%E5%89%8D%E5%8D%81%E5%90%8D%E8%82%A1%E4%B8%9C%E6%8C%81%E8%82%A1%E6%83%85%E5%86%B5%E8%A1%A8) As of the end of the reporting period, the company had **39,388** common shareholders, with controlling shareholder Su Enben holding **39.59%**, indicating a relatively concentrated equity structure, and Su Enben, Su Enkui, and Yunnan Aiji Business Information Consulting Co Ltd have an associated relationship among the top ten shareholders - As of the end of the reporting period, the company had **39,388** common shareholders[10](index=10&type=chunk) Top Five Shareholders' Shareholding Status | Shareholder Name | Number of Shares Held (shares) | Shareholding Percentage (%) | | :--- | :--- | :--- | | Su Enben | 144,050,211 | 39.59 | | Yunnan Aiji Business Information Consulting Co Ltd | 15,848,959 | 4.36 | | Huatai Zijin (Jiangsu) Equity Investment Fund (Limited Partnership) | 5,854,933 | 1.61 | | Xu Xingde | 4,459,046 | 1.23 | | Su Enkui | 4,091,102 | 1.12 | - Shareholders Su Enben and Su Enkui are brothers, and Su Enben is the de facto controller of Yunnan Aiji Business Information Consulting Co Ltd, indicating an associated relationship among the three[11](index=11&type=chunk) [Quarterly Financial Statements](index=6&type=section&id=%E5%9B%9B%E3%80%81%20%E5%AD%A3%E5%BA%A6%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) This section presents the detailed consolidated and parent company financial statements for the quarter [Consolidated Financial Statements](index=7&type=section&id=%E5%90%88%E5%B9%B6%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) The consolidated financial statements reflect the company's overall financial position and operating results, showing significant growth in total assets, operating revenue, and net profit, along with substantial improvement in operating cash flow, indicating a healthy financial status and strong growth potential in Q1 2022 [Consolidated Balance Sheet](index=7&type=section&id=%E5%90%88%E5%B9%B6%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8) As of March 31, 2022, the company's total assets reached **3.56 billion CNY**, a **13.50%** increase from the end of the previous year, primarily driven by increased accounts receivable and inventory due to expanded sales, while liabilities saw a notable rise in short-term borrowings and contract liabilities from increased advance receipts Key Items from Consolidated Balance Sheet | Item | March 31, 2022 (CNY) | December 31, 2021 (CNY) | Change (%) | | :--- | :--- | :--- | :--- | | Cash and Cash Equivalents | 1,045,820,980.65 | 968,903,398.28 | 7.94% | | Accounts Receivable | 614,118,936.49 | 438,761,505.96 | 39.97% | | Inventory | 345,351,006.00 | 252,302,718.06 | 36.88% | | **Total Assets** | **3,561,523,415.57** | **3,137,931,357.50** | **13.50%** | | Short-term Borrowings | 539,068,012.20 | 464,365,605.30 | 16.09% | | Contract Liabilities | 228,112,901.45 | 94,293,039.09 | 141.92% | | **Total Liabilities** | **1,063,060,718.60** | **863,901,587.25** | **23.05%** | | Total Equity Attributable to Parent Company Shareholders | 2,325,734,004.11 | 2,106,400,196.02 | 10.41% | | **Total Liabilities and Equity** | **3,561,523,415.57** | **3,137,931,357.50** | **13.50%** | [Consolidated Income Statement](index=9&type=section&id=%E5%90%88%E5%B9%B6%E5%88%A9%E6%B6%A6%E8%A1%A8) In Q1 2022, the company achieved operating revenue of **570.72 million CNY**, a **106.80%** year-over-year increase, and net profit attributable to the parent company of **218.72 million CNY**, a **249.06%** year-over-year increase, with expenses growing in line with revenue scale, but profit growth significantly outpaced revenue and cost growth, indicating a substantial improvement in profitability Key Items from Consolidated Income Statement | Item | Q1 2022 (CNY) | Q1 2021 (CNY) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Total Operating Revenue | 570,715,217.73 | 275,980,165.77 | 106.80% | | Operating Cost | 170,484,059.91 | 103,638,277.49 | 64.50% | | Selling Expenses | 62,029,701.94 | 44,836,335.34 | 38.35% | | Administrative Expenses | 28,504,718.45 | 17,643,636.75 | 61.56% | | R&D Expenses | 50,924,275.03 | 35,937,615.18 | 41.70% | | Total Profit | 243,478,180.85 | 74,251,540.74 | 227.91% | | Net Profit Attributable to Parent Company Shareholders | 218,721,114.67 | 62,660,788.00 | 249.06% | | Basic Earnings Per Share (CNY/share) | 0.61 | 0.17 | 258.82% | [Consolidated Cash Flow Statement](index=11&type=section&id=%E5%90%88%E5%B9%B6%E7%8E%B0%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) During the reporting period, net cash flow from operating activities was **66.90 million CNY**, a substantial **465.85%** year-over-year increase, primarily due to increased cash received from sales of goods and services, while investing activities resulted in a net outflow of **15.62 million CNY** and financing activities a net inflow of **51.38 million CNY** Consolidated Cash Flow Statement Summary | Item | Q1 2022 (CNY) | Q1 2021 (CNY) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 66,898,060.91 | 11,822,523.50 | | Net Cash Flow from Investing Activities | -15,619,831.84 | -11,256,347.15 | | Net Cash Flow from Financing Activities | 51,380,646.72 | 14,019,955.51 | | Net Increase in Cash and Cash Equivalents | 100,071,255.50 | 16,042,500.48 | [Parent Company Financial Statements](index=13&type=section&id=%E6%AF%8D%E5%85%AC%E5%8F%B8%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) The parent company financial statements reflect the operational performance of the company's headquarters, showing high-speed growth in both operating revenue and net profit consistent with consolidated trends, indicating strong growth momentum in core businesses [Parent Company Balance Sheet](index=13&type=section&id=%E6%AF%8D%E5%85%AC%E5%8F%B8%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8) As of the end of the period, the parent company's total assets were **3.61 billion CNY**, a **24.77%** increase from the end of the previous year, with significant increases in current assets including cash and cash equivalents, accounts receivable, prepayments, and other receivables, reflecting business expansion Key Items from Parent Company Balance Sheet | Item | March 31, 2022 (CNY) | December 31, 2021 (CNY) | | :--- | :--- | :--- | | **Total Assets** | **3,605,705,988.93** | **2,889,828,630.74** | | **Total Liabilities** | **1,459,741,420.40** | **943,266,945.69** | | **Total Equity** | **2,145,964,568.53** | **1,946,561,685.05** | [Parent Company Income Statement](index=16&type=section&id=%E6%AF%8D%E5%85%AC%E5%8F%B8%E5%88%A9%E6%B6%A6%E8%A1%A8) In Q1 2022, the parent company achieved operating revenue of **478.39 million CNY**, a **241.11%** year-over-year increase, and net profit of **198.95 million CNY**, a **319.56%** year-over-year increase, with growth rates exceeding those of the consolidated statements, indicating strong performance in the parent company's core businesses Key Items from Parent Company Income Statement | Item | Q1 2022 (CNY) | Q1 2021 (CNY) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 478,388,322.47 | 140,244,399.70 | 241.11% | | Operating Profit | 222,310,952.13 | 49,831,012.29 | 346.14% | | Net Profit | 198,949,409.07 | 47,418,407.29 | 319.56% | [Parent Company Cash Flow Statement](index=17&type=section&id=%E6%AF%8D%E5%85%AC%E5%8F%B8%E7%8E%B0%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) During the reporting period, the parent company's net cash flow from operating activities was **156.90 million CNY**, a significant improvement from **32.00 million CNY** in the same period last year, primarily due to cash received from sales of goods increasing from **164.00 million CNY** to **457.00 million CNY** Parent Company Cash Flow Statement Summary | Item | Q1 2022 (CNY) | Q1 2021 (CNY) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 156,898,245.03 | 31,997,859.17 | | Net Cash Flow from Investing Activities | -24,335,842.83 | -30,604,488.22 | | Net Cash Flow from Financing Activities | 27,663,852.85 | -31,692,515.63 |

2021 年第三季度报告 证券代码：603387 证券简称：基蛋生物 基蛋生物科技股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 单位：元 币种：人民币 2 / 16 | 项目 | 本报告期 | 本报告期 | 年初至报告期末 | 年初至报告期 | | --- | --- | --- | --- | --- | | | | 比上年同 | | 末比上年同期 | | | | 期增减变 | | 增减变动幅度 | | | | 动幅度(%) | | (%) | | 营业收入 | 321,868,116.11 ...